The damage can be silent, cumulative, and permanent. For cancer patients undergoing treatment with powerful chemotherapies, the threat to the heart is a secondary, often devastating, complication. Current monitoring is episodic, relying on periodic echocardiograms or ECGs in a clinic, a snapshot that can miss the moment of onset. Skribe Medical, a Mill Valley-based startup founded in 2024, is betting that the answer lies in a battery-free, multi-sensor patch that harvests energy from the body itself.
Its target is the field of cardio-oncology. The company’s proposed solution is an end-to-end system: lightweight wearable sensors that use Resonant Body Power technology to harvest energy and transmit data to a companion smartwatch, paired with deep learning algorithms designed to detect early signs of cardiac dysfunction [Skribe Medical].
A founding team forged in FDA clearance
The three co-founders, CEO Ryan Neely, CTO Josh Kay, and CSO Andrew Bohannon, all worked together previously at iota Biosciences, a company known for developing ultra-miniature, implantable bioelectronic devices [Marin Sonoma Impact Ventures]. This shared history is Skribe’s most tangible asset. The team’s collective experience includes taking novel medical device technology from concept to FDA clearance [Marin Sonoma Impact Ventures].
| Founder | Role | Prior Experience |
|---|---|---|
| Ryan Neely, Ph.D. | CEO | Director of Systems & Design, iota Biosciences; Ph.D., UC Berkeley [The Org, 2026] |
| Josh Kay | CTO | Engineering roles at iota Biosciences and Integral [RocketReach, 2026] |
| Andrew Bohannon | CSO | Lead Neuroscientist & Director of Bioelectronic Medicine, iota Biosciences [Apollo.io, 2026] |
The technical wedge: continuous versus episodic
Skribe’s proposed advantage hinges on a shift from intermittent to continuous monitoring. The use of Resonant Body Power for a battery-free patch is a notable differentiator, aiming to improve patient comfort and compliance by eliminating the need for frequent charging [Skribe Medical].
Navigating a landscape of evidence and competition
Skribe has not yet publicized any clinical partnerships, pilot deployments, or regulatory submissions. Its immediate competitor appears to be Strados Labs, which offers FDA-cleared wearable sensors for respiratory monitoring [Strados Labs].
The patient at the center
Skribe Medical’s ambition is to replace the reactive paradigm with a preventive one. If its technology works as hoped, a clinician could receive an alert that a patient’s cardiac strain is trending upward, potentially allowing for a medication adjustment before permanent damage occurs.